API | temocillin

temocillin Report issue

Small molecule Experimental

AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW

Temocillin is a β-lactamase-resistant penicillin introduced by Beecham, marketed by Eumedica Pharmaceuticals as Negaban. It is used primarily for the treatment of multiple drug-resistant, Gram-negative bacteria. It is a 6-methoxy penicillin; it is also a carboxypenicillin. ^Wikipedia

Chemistry

SMILES: CO[C@@]1(NC(=O)C(C(=O)O)c2ccsc2)C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@@H]21
InChIKey: BVCKFLJARNKCSS-DWPRYXJFSA-N
Mol. Mass: 414.46
ALogP: 0.52 Partition coefficient
ChEMBL Molecule:
temocillin

More Chemistry

Pharmacology

Mechanisms of Action:
- Cell division protein FtsI (Peptidoglycan synthetase) (Staphylococcus aureus) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Organizations (13)

Research & Development (13)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (9)

Approved Indications (1)

Bacterial Infections

Experimental Indications - Clinical Trial Phases 1-4 (8)

Bacteremia (Phase 3)

Gram-Negative Bacterial Infections (Phase 4)

Infections (Phase 4)

Kidney Diseases (Phase 4)

Liver Diseases (Phase 4)

Sepsis (Phase 3)

Shock, Septic (Phase 3)

Urinary Tract Infections (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 9
# of Trial Organizations: 13

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue